StockNews.com assumed coverage on shares of DURECT (NASDAQ:DRRX – Get Free Report) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
DURECT Stock Down 5.0 %
Shares of DURECT stock opened at $0.81 on Thursday. The stock’s fifty day moving average is $0.80 and its two-hundred day moving average is $1.01. DURECT has a 52 week low of $0.70 and a 52 week high of $1.88. The company has a market capitalization of $25.02 million, a PE ratio of -1.32 and a beta of 0.91.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its stake in DURECT by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock worth $429,000 after acquiring an additional 14,658 shares in the last quarter. Richmond Brothers Inc. raised its stake in shares of DURECT by 12.2% during the fourth quarter. Richmond Brothers Inc. now owns 1,281,176 shares of the specialty pharmaceutical company’s stock valued at $961,000 after acquiring an additional 138,920 shares in the last quarter. Finally, Jane Street Group LLC boosted its holdings in shares of DURECT by 266.0% in the fourth quarter. Jane Street Group LLC now owns 39,196 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 28,486 shares during the period. Hedge funds and other institutional investors own 28.03% of the company’s stock.
DURECT Company Profile
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
Featured Stories
- Five stocks we like better than DURECT
- What Are Growth Stocks and Investing in Them
- Energy Transfer: Powering Data With Dividends and Diversification
- Pros And Cons Of Monthly Dividend Stocks
- Qualcomm Stock Is Coiling for a Breakout
- What is the MACD Indicator and How to Use it in Your Trading
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.
